HMG-CoA reductase inhibitors (statins) are established drugs for the treatment of hypercholesterolemia. Furthermore, they induce regression of vascular atherosclerosis as well as reduction of cardiovascular-related morbidity and death in patients with and without coronary artery disease. This book deals with statins which have substantially altered the approach to therapy of atherosclerosis and its sequelae. Emphasis is placed on the scientific background to the discoveries and the development of the therapy, including an overview of the current state of knowledge of the drugs. Clinical data are reviewed extensively. This book not only provides the reader with valuable information but also stimulates further research into the pathogenesis of atherosclerosis and the mechanisms behind the action of effective statins. It sets the stage for creative thinking among scientists of many disciplines for the accomplishment of our ultimate goals in treating atherosclerosis and its sequelae. This topical volume...

Includes supplementary material: sn.pub/extras

Inhalt
History and development of HMG-CoA reductase inhibitors.- Structure and mechanisms of action of HMG-CoA reductase inhibitors.- Sterol-regulatory element binding proteins (SREBPs): gene-regulatory target of statin action.- Cellular effects of HMG-CoA reductase inhibitors on blood cells (monocytes, macrophages, platelets).- Pleiotropic effects of HMG-CoA reductase inhibitors on cells of the vascular wall.- Indications and contra-indications for statin treatment (primary and secondary prevention of hypercholesterolemia).- Clinical experience: studies with HMG-CoA reductase inhibitors.- Cost-effectiveness of statins in primary and secondary prevention of coronary heart disease.